Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.86 Million USD | -127.36% |
| 2022 | -15.77 Million USD | 15.93% |
| 2021 | -18.76 Million USD | 23.07% |
| 2020 | -24.39 Million USD | -38.91% |
| 2019 | -17.56 Million USD | 75.7% |
| 2018 | -72.27 Million USD | 25.81% |
| 2017 | -97.42 Million USD | -28.15% |
| 2016 | -76.02 Million USD | -57.22% |
| 2015 | -48.35 Million USD | -150.65% |
| 2014 | -19.29 Million USD | -6.94% |
| 2013 | -18.04 Million USD | -48.21% |
| 2012 | -12.17 Million USD | 11.67% |
| 2011 | -13.78 Million USD | -76.98% |
| 2010 | -7.78 Million USD | -59.71% |
| 2009 | -4.87 Million USD | 8.02% |
| 2008 | -5.3 Million USD | 25.28% |
| 2007 | -7.09 Million USD | -3562.93% |
| 2006 | -193.69 Thousand USD | 89.25% |
| 2005 | -1.8 Million USD | -247.66% |
| 2004 | -518.14 Thousand USD | -5081.43% |
| 2003 | -10 Thousand USD | 0.0% |
| 2002 | -10 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -7.08 Million USD | 16.49% |
| 2023 Q4 | -8.52 Million USD | -20.3% |
| 2023 FY | - USD | -127.36% |
| 2023 Q1 | -11.82 Million USD | -23.01% |
| 2023 Q2 | -8.48 Million USD | 28.24% |
| 2022 Q1 | -3.51 Million USD | 55.33% |
| 2022 Q2 | -1.46 Million USD | 58.22% |
| 2022 FY | - USD | 15.93% |
| 2022 Q4 | -9.61 Million USD | -96.71% |
| 2022 Q3 | -4.88 Million USD | -232.68% |
| 2021 Q1 | -9.06 Million USD | 3.55% |
| 2021 Q3 | -4.36 Million USD | 59.04% |
| 2021 FY | - USD | 23.07% |
| 2021 Q4 | -7.87 Million USD | -80.32% |
| 2021 Q2 | -10.65 Million USD | -17.58% |
| 2020 Q2 | -6.57 Million USD | -2.99% |
| 2020 Q4 | -9.39 Million USD | -84.71% |
| 2020 FY | - USD | -38.91% |
| 2020 Q1 | -6.38 Million USD | -20.88% |
| 2020 Q3 | -5.08 Million USD | 22.64% |
| 2019 Q2 | -3.76 Million USD | -5.03% |
| 2019 Q1 | -3.58 Million USD | -145.28% |
| 2019 Q3 | -4.93 Million USD | -31.33% |
| 2019 FY | - USD | 75.7% |
| 2019 Q4 | -5.28 Million USD | -6.99% |
| 2018 Q3 | -21.72 Million USD | -53.41% |
| 2018 Q1 | -13.17 Million USD | 34.73% |
| 2018 FY | - USD | 25.81% |
| 2018 Q4 | 7.9 Million USD | 136.39% |
| 2018 Q2 | -14.16 Million USD | -7.49% |
| 2017 FY | - USD | -28.15% |
| 2017 Q1 | -20.41 Million USD | -20.36% |
| 2017 Q2 | -32.5 Million USD | -59.22% |
| 2017 Q4 | -20.18 Million USD | 26.69% |
| 2017 Q3 | -27.54 Million USD | 15.27% |
| 2016 Q2 | -16.43 Million USD | -6.17% |
| 2016 FY | - USD | -57.22% |
| 2016 Q4 | -16.96 Million USD | 29.92% |
| 2016 Q3 | -24.2 Million USD | -47.23% |
| 2016 Q1 | -15.48 Million USD | 22.18% |
| 2015 Q4 | -19.89 Million USD | -38.76% |
| 2015 FY | - USD | -150.65% |
| 2015 Q2 | -13.52 Million USD | 1.79% |
| 2015 Q3 | -14.33 Million USD | -6.0% |
| 2015 Q1 | -13.77 Million USD | -105.14% |
| 2014 Q4 | -6.71 Million USD | -36.33% |
| 2014 Q1 | -2.53 Million USD | 56.98% |
| 2014 FY | - USD | -6.94% |
| 2014 Q3 | -4.92 Million USD | 17.05% |
| 2014 Q2 | -5.93 Million USD | -134.17% |
| 2013 FY | - USD | -48.21% |
| 2013 Q4 | -5.89 Million USD | 24.38% |
| 2013 Q3 | -7.79 Million USD | -157.69% |
| 2013 Q1 | -5.21 Million USD | -160.18% |
| 2013 Q2 | -3.02 Million USD | 42.02% |
| 2012 Q3 | -2.23 Million USD | 36.89% |
| 2012 Q4 | -2 Million USD | 10.27% |
| 2012 FY | - USD | 11.67% |
| 2012 Q1 | -3.18 Million USD | 0.64% |
| 2012 Q2 | -3.54 Million USD | -11.07% |
| 2011 Q2 | -3.55 Million USD | -5.6% |
| 2011 FY | - USD | -76.98% |
| 2011 Q4 | -3.2 Million USD | 18.44% |
| 2011 Q1 | -3.36 Million USD | -14.96% |
| 2011 Q3 | -3.93 Million USD | -10.7% |
| 2010 Q2 | -1.73 Million USD | 0.69% |
| 2010 Q1 | -1.74 Million USD | -12.17% |
| 2010 Q3 | -2.77 Million USD | -59.89% |
| 2010 Q4 | -2.92 Million USD | -5.66% |
| 2010 FY | - USD | -59.71% |
| 2009 FY | - USD | 8.02% |
| 2009 Q4 | -1.55 Million USD | 21.95% |
| 2009 Q2 | -1.43 Million USD | -93.2% |
| 2009 Q1 | -745.03 Thousand USD | -6.72% |
| 2009 Q3 | -1.99 Million USD | -38.48% |
| 2008 Q2 | -1.21 Million USD | 24.44% |
| 2008 Q4 | -698.11 Thousand USD | 33.39% |
| 2008 Q3 | -1.04 Million USD | 13.42% |
| 2008 Q1 | -1.6 Million USD | -11.22% |
| 2008 FY | - USD | 25.28% |
| 2007 Q2 | -2.83 Million USD | -5224.36% |
| 2007 Q3 | -1.75 Million USD | 37.97% |
| 2007 Q4 | -1.44 Million USD | 18.0% |
| 2007 FY | - USD | -3562.93% |
| 2007 Q1 | -53.19 Thousand USD | 97.83% |
| 2006 Q4 | -2.45 Million USD | -234.09% |
| 2006 Q1 | -748.82 Thousand USD | -60.43% |
| 2006 FY | - USD | 89.25% |
| 2006 Q2 | -807.44 Thousand USD | -7.83% |
| 2006 Q3 | 1.82 Million USD | 326.56% |
| 2005 Q4 | -466.75 Thousand USD | -2.24% |
| 2005 Q3 | -456.51 Thousand USD | -11.26% |
| 2005 Q1 | -724.86 Thousand USD | -200.72% |
| 2005 FY | - USD | -247.66% |
| 2005 Q2 | -410.3 Thousand USD | 43.4% |
| 2004 Q4 | -241.04 Thousand USD | 0.0% |
| 2004 FY | - USD | -5081.43% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 49.506% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -504.985% |
| SQZ Biotechnologies Company | -64.14 Million USD | 44.078% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -106.5% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 138.143% |
| Mesoblast Limited | -62.38 Million USD | 42.508% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2235.147% |
| Genus plc | 73.7 Million USD | 148.669% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -442.523% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -911.25% |
| Marizyme, Inc. | -34.28 Million USD | -4.631% |
| ContraFect Corporation | -64.99 Million USD | 44.816% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -308.903% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -692.476% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2458.767% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1256.389% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1443.536% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -6823.903% |
| Accustem Sciences Inc. | -3.74 Million USD | -857.421% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 25.625% |
| EV Biologics, Inc. | -1.26 Million USD | -2730.723% |
| Q BioMed Inc. | -617.62 Thousand USD | -5707.541% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1104.171% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -5571.831% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1470.11% |
| Biomind Labs Inc. | -1.03 Million USD | -3367.115% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 463.157% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -400.874% |
| Skye Bioscience, Inc. | -13.54 Million USD | -164.764% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2311.504% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -143376.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -823.431% |
| IMV Inc. | -35.52 Million USD | -0.973% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -126.021% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1333.635% |
| GB Sciences, Inc. | -1.41 Million USD | -2426.191% |
| Alpha Cognition Inc. | -9.7 Million USD | -269.57% |
| HST Global, Inc. | -5303.00 USD | -676290.722% |
| CSL Limited | 4.78 Billion USD | 100.749% |
| Halberd Corporation | -74.27 Thousand USD | -48189.557% |
| Enzolytics Inc. | -2.12 Million USD | -1590.316% |
| Resverlogix Corp. | -11.74 Million USD | -205.476% |
| Affymax, Inc. | -14.29 Million USD | -150.92% |
| SYBLEU INC | -141.57 Thousand USD | -25236.404% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1071.035% |
| argenx SE | -216.02 Million USD | 83.396% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 35.183% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 3047.329% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2293.012% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 9568.013% |
| AVAX Technologies, Inc. | -6.11 Million USD | -486.8% |
| Zenith Capital Corp. | -8.6 Million USD | -316.791% |
| Genscript Biotech Corporation | -248.71 Million USD | 85.579% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -205795.184% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1366.159% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -20277.293% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 9.506% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1140.144% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -3328.136% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 533547.353% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1949.658% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1767.291% |
| BioStem Technologies, Inc. | -7.55 Million USD | -374.857% |
| ONE Bio Corp. | 13.61 Million USD | 363.49% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -19707.497% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1643.753% |
| Agentix Corp. | -1.37 Million USD | -2514.824% |
| LadRx Corporation | 412.28 Thousand USD | 8800.092% |
| Cell Source, Inc. | -4.27 Million USD | -739.527% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -9667.688% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2546.799% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -3728.277% |
| NovAccess Global Inc. | -1.03 Million USD | -3366.284% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 505.125% |
| Itoco Inc. | -1.86 Million USD | -1819.16% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -9348.659% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3114.068% |
| Kadimastem Ltd | -2.62 Million USD | -1266.76% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -14898.536% |
| CytoDyn Inc. | -18.02 Million USD | -98.952% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -45287.136% |
| Mobile Lads Corp. | -2.24 Million USD | -1500.467% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -293210.982% |
| Qrons Inc. | -40.08 Thousand USD | -89391.28% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -7285.346% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 6900.674% |
| Rebus Holdings, Inc. | -951 Thousand USD | -3671.714% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -3277.463% |
| International Stem Cell Corporation | 202 Thousand USD | 17856.931% |
| Bioxytran, Inc. | -3.82 Million USD | -838.943% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -68040.198% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1356.945% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -79608.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1210.044% |
| Neutra Corp. | -181.24 Thousand USD | -19690.121% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -77.93% |
| PureTech Health plc | -11.62 Million USD | -208.497% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -77.943% |
| IXICO plc | -707 Thousand USD | -4973.409% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -366.74% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 25.808% |
| CSL Limited | 4.73 Billion USD | 100.758% |
| Cellectis S.A. | -92.63 Million USD | 61.28% |